Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients

Jacob J. Chabon(Foresight Science & Technology (United States)), Maximilian Diehn(Stanford University)

Nature Communications

June 10, 2016

10.1038/ncomms11815

Cited by 657

Related Papers

Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review

|Journal of Clinical Oncology|2018|925

Integrating genomic features for non-invasive early lung cancer detection

|Nature|2020|689

Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer

|Journal of Thoracic Oncology|2021|642

Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non–Small Cell Lung Cancer

|JAMA Oncology|2017|600

Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer

|Nature Cancer|2020|369